Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Fospropofol + fentanyl** is a pharmaceutical combination used for the induction and maintenance of procedural sedation and anesthesia in medical settings, particularly during minor surgical procedures and diagnostic interventions. **Fospropofol** is a water-soluble prodrug of propofol, metabolized in the body to release active propofol, providing sedative and hypnotic effects. **Fentanyl** is a potent synthetic opioid analgesic that acts on μ-opioid receptors, providing rapid and profound analgesia and contributing to sedation. The combination is typically administered intravenously, with fentanyl given prior to fospropofol to enhance analgesia and facilitate a smoother induction of sedation or anesthesia. This regimen has demonstrated efficacy in achieving deep sedation with rapid recovery and high patient and clinician satisfaction. It is commonly used in procedures such as endoscopy and bronchoscopy, and especially in settings where pain and discomfort must be minimized with rapid post-procedure recovery[4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fospropofol + fentanyl.